Also
- Share via
Elan Corp. and American Home Products Corp. stopped work on an Alzheimer’s treatment after 15 patients developed inflammation of the central nervous system. Although no more patients will receive AN-1792, the companies said they would continue to work on other experimental Alzheimer’s drugs.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
